The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Series C Financing

24 Jul 2006 07:02

Amphion Innovations PLC24 July 2006 AMPHION INNOVATIONS PLC PARTNER COMPANY SUPERTRON RAISES $3.5 MILLION IN SERIES C FINANCING July 24 2006 - Amphion Innovations plc today announced that one of its partnercompanies, Supertron Technologies, Inc. a leading developer of next-generationsolutions for high-performance preclinical and clinical Magnetic ResonanceImaging (MRI) coils, probes and accessories, has raised $3.5 million in a SeriesC financing. The round was originally intended to close at $3 million, but the financingincreased due to overwhelming investor demand. As a result of this financing thevalue of Amphion's investment in Supertron will increase from $1.1 million at 31December 2005 to $3.6 million. Amphion's strategy is to invest in and support the growth process of companies,like Supertron, that answer broad-based, unmet market needs with provensolutions and predictable results. Supertron's products dramatically improve theimaging capabilities of conventional MRI scanners. The products greatly enhancethe MRI image quality, reduce scan time in existing scanners and greatly lowerthe cost. These factors ultimately result in earlier disease detection, fasterdrug development, and integrated and/or guided therapeutics. In addition to designing clinical and pre-clinical MRI coils, Supertron is alsodesigning cryogenic coils that increase speed and allow for imaging of bodyparts in motion. The cryogenic coils also improve resolution, which enablesdoctors to see smaller structures. Its solutions are applicable in both high andlow-field clinical, preclinical and research scanning environments. Supertron is also targeting emerging MRI research applications in the fields ofmolecular imaging, image-guided therapeutics, image-guided surgery, andorthopedics imaging. The company is currently developing a number ofnext-generation MRI products in neuro imaging and pre-clinical imaging. Based in Newark, NJ, Supertron has filed four patents and has collaborated inpartnership with Harvard Medical School, Columbia University, StanfordUniversity, University of Medicine and Dentistry of New Jersey, New JerseyInstitute of Technology and University of Queensland, Australia. "We are very pleased that investors and partners recognize the potential inSupertron which is at the forefront of innovations in life sciences," saidRichard C.E. Morgan, Chief Executive Officer of Amphion. "Clearer and fasterMRIs will help doctors detect diseases earlier and it will help researchersdramatically reduce the time it takes to get vitally important new drugs tomarket." The latest round of financing will support product development, intellectualproperty management, critical staffing, marketing, financing fees and costs, andpotential acquisitions. "We are excited by the market response to our offering and the recognition ofthe value of our gateway to improved performance for the magnetic resonanceimaging industry as a whole, which our product and technology set offers," saidC. Richard Hullihen, Chief Executive Officer of Supertron. For more information please contact: Amphion Innovations plcJosh Berkman, Media Relations +1 (646) 747-7158 SupertronCameron Barnard +1 973 639 1112 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert About Supertron Supertron is a market leading developer and manufacturer of superconducting andcryogenically cooled preclinical and clinical MRI coils and accessories.Supertron's gateway technology MRI coils have demonstrated capability ofdramatically increasing speed and resolution of the MRI scanner. Supertron'scoils have been demonstrated at leading medical institutions such as ColumbiaPresbyterian, Brigham and Women's Hospital, Harvard Medical School, DukeUniversity, and overseas at Hong Kong University. On the Web: www.supertron.com About Amphion Innovations plcAmphion Innovations plc is listed on the AIM Exchange in London under the symbolAMP. Amphion develops and operates companies in the life science and medicaltechnology markets, working in partnership with corporations, governments,universities, and entrepreneurs seeking to commercialize their intellectualproperty using its proven company creation and building process. On the Web: www.amphionplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.